XVIVO Perfusion Interim report January – September 2016

CONTINUED GROWTH AND POSITIVE OPERATING CASH-FLOW

THIRD QUARTER 2016 (JUL – SEP)

• Net sales in the quarter amounted to SEK 31.7 (26.6) million, corresponding to an increase of 19 percent. The acquisition of Vivoline had a positive impact of SEK 1.6 million on sales. Adjusted for this, growth amounted to 13 percent in SEK and 12 in local currency.
• Operating income before depreciation and amortization (EBITDA) excluding items effecting comparability increased by 22 percent and amounted to SEK 5.4 (4.4) million, corresponding to an EBITDA margin of 17 percent. Items effecting comparability of SEK 2.7 million related to the Nasdaq Stockholm main market listing and the acquisition of Vivoline have been charged against the quarter. EBITDA amounted to SEK 2.7 (4.4) million, corresponding to an EBITDA margin of 9 percent.
• Operating income amounted to SEK -0.7 (1.5) million, after amortization and depreciation of SEK 3.5 (2.9) million was charged against the quarter.
• Net income amounted to SEK -0.6 (1.3) million, resulting in earnings per share of SEK -0.02 (0.06).
• Cash flow from operating activities was SEK 5.4 (2.8) million.
• Total sales from warm perfusion (STEEN Solution™, XPS™, LS™ and products and services related to the use of the XPS™ and LS™) accounted for 35 (29) percent of the total sales.
• 2 XPS™ contracts were signed in the USA during the quarter.
• During the quarter XVIVO Perfusion acquired another 1.6 percent of the shares and 0.7 percent of the 2015/2016 warrants in the listed company Vivoline Medical AB, whereby XVIVO Perfusion became the owner of 98.6 percent of the shares and 99.6 percent of the warrants. The compulsory redemption process was initiated. Vivoline’s shares and warrants were delisted from Nasdaq First north on July 8, 2016..

THE PERIOD 2016 (JAN – SEP)

• Net sales in the period amounted to SEK 99.8 (87.6) million, corresponding to an increase of 14 percent. The acquisitions of Vivoline had a positive impact of SEK 1.6 million on sales. Adjusted for this, growth amounted to 12 percent in SEK and 12 in local currency.
• Operating income before depreciation and amortization (EBITDA) excluding items effecting comparability increased by 45 percent and amounted to SEK 19.7 (13.6) million, corresponding to an EBITDA margin of 20 percent. Items effecting comparability of SEK 7.3 million related to the Nasdaq Stockholm main market listing and the acquisition of Vivoline have been charged against the period. EBITDA amounted to SEK 12.4 (11.9) million, corresponding to an EBITDA margin of 12 percent.
• Operating income amounted to SEK 2.7 (3.4) million, after amortization and depreciation of SEK 9.7 (8.5) million was charged against the period.
• Net income amounted to SEK 2.1 (2.3) million, resulting in earnings per share of SEK 0.09 (0.11).
• Cash flow from operating activities was SEK 18.7 (5.7) million.
• Total sales from warm perfusion (STEEN Solution™, XPS™, LS™ and products and services related to the use of the XPS™ and LS™) accounted for 39 (38) percent of the total sales.
• During the period 6 XPS™ were sold, of which 2 to Europe and 4 to the US. France and Switzerland were new countries that got access to the XPS™ during the period.
• XVIVO Perfusion AB’s shares were admitted for trading on Nasdaq First North Premier 8 February 2016. The company's shares will continue trading with the same short name and ISIN code.

SIGNIFICANT EVENTS AFTER THE END OF THE QUARTER

• Two LS™ contracts were signed in Spain after the end of the quarter.

CONFERENCE CALL

CEO Magnus Nilsson will present the report in a conference call at 3 p.m. CET on Thursday, October 27, 2016. Telephone: +44 (0) 2071 928 000, enter code 94108581.

October 27, 2016
Gothenburg
XVIVO Perfusion AB (publ)
Magnus Nilsson, CEO 

* LS-1 is the Vivoline EVLP machine.

For further information please contact:

Christoffer Rosenblad, CFO, +1 720 616 2101, christoffer.rosenblad@xvivoperfusion.com
Magnus Nilsson, CEO, +46 31 788 2150, magnus.nilsson@xvivoperfusion.com
For further information on XVIVO Perfusion’s business, please refer to the company’s website, www.xvivoperfusion.com

This information is information that Xvivo Perfusion AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m CET on October 27, 2016.

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.

______________________________________________________________________________________________________________________

XVIVO Perfusion AB is a medical technology company which develops solutions and systems for assessing and preserving organs outside the body and for selecting usable organs and maintaining them in optimal condition pending transplantation.
The company is headquartered in Gothenburg, Sweden, and has one office in Lund, Sweden and one office in Denver, the USA. The XVIVO share is listed on NASDAQ First North premier and has the ticker symbol XVIVO. More information can be found on the website www.xvivoperfusion.com. The Certified Adviser is Redeye, www.redeye.se.
______________________________________________________________________________________________________________________

XVIVO Perfusion AB (publ), Box 53015, SE-400 14 Göteborg. Corporate identity number 556561-0424.
Tel: 46 31 788 21 50. Fax: 46 31 788 21 69.
E-mail: info@xvivoperfusion.com. Website: www.xvivoperfusion.com

Tags: